戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ct that can be prevented by treatment with a calcimimetic.
2  making it a highly differentiated precision calcimimetic.
3 nificantly improves cortical BMD compared to calcimimetics.
4 osphonates, hormone replacement therapy, and calcimimetics.
5 in the ECD and 7TMD and the 7TMD site(s) for calcimimetics.
6 sphonates, and a new class of drugs known as calcimimetics.
7 ellular Ca2+ at the Ca2+ receptor are termed calcimimetics.
8 mped rats the bone effects of calcitriol and calcimimetic administration.
9 iven single orally administered doses of the calcimimetic agent AMG 073 ranging from 5 to 100 mg, or
10 aluating the safety and effectiveness of the calcimimetic agent cinacalcet hydrochloride.
11 as been hypothesized that treatment with the calcimimetic agent cinacalcet might reduce the risk of d
12  posttransplant hyperparathyroidism with the calcimimetic agent cinacalcet.
13                           However, with each calcimimetic agent, the decreases in PTH from baseline w
14 f hyperphosphatemia on the responsiveness to calcimimetic agents appears relatively modest, however,
15                                              Calcimimetic agents are a new class of drugs that increa
16 oviders of dialysis thus have suggested that calcimimetic agents are ineffective and should not be us
17                                              Calcimimetic agents directly inhibit PTH secretion by ac
18 oidism will indicate whether the efficacy of calcimimetic agents extends into the longer term.
19               The efficacy of treatment with calcimimetic agents for lowering plasma PTH levels among
20 discover potent, orally bioavailable type II calcimimetic agents for the treatment of secondary hyper
21                                        These calcimimetic agents hold promise as potential treatments
22  the administration of vitamin D analogs and calcimimetic agents may be augmented in the future by ag
23 temia diminishes the therapeutic response to calcimimetic agents, we used data from large clinical tr
24 m receptor activation by calcium ions and by calcimimetic agents.
25 ic CaSR -/- (TS-CaSR -/- ) mice treated with calcimimetics, alkali, or acid, and Klotho shed from min
26                                          Two calcimimetic allosteric modulators, NPS R-568 and Calind
27                         We hypothesized that calcimimetics, allosteric modulators of the calcium-sens
28                           In this study, the calcimimetic AMG 073 at doses up to 100 mg for 18 wk pro
29 approaches to the synthesis of new and known calcimimetic analogues employing enantiopure (1-naphthal
30                                              Calcimimetics and HCO 3 increase serum sKlotho levels in
31 tentiated by allosteric activators including calcimimetics and l-amino acids.
32                               CaSR agonists (calcimimetics) and antagonists (calcilytics) have been i
33 te calcium concentration, vitamin K therapy, calcimimetics, and antiresorptive agents had conflicting
34 to sensing amino acids, GPRC6A is a cation-, calcimimetic-, and osteocalcin-sensing receptor and a ca
35                               Calcitriol and calcimimetics are used to treat hyperparathyroidism seco
36 ow that the administration of calcitriol and calcimimetic at doses that induced a similar reduction i
37 lusion, besides the action of calcitriol and calcimimetics at parathyroid level, these treatments hav
38 SR revealed conservation of both calcium and calcimimetic binding sites.
39          No patients received treatment with calcimimetics, bisphosphonates, vitamin D, or phosphate
40 pressing the CaSR and Klotho, in response to calcimimetics, calcilytics, alkalotic and acidic pH, and
41              Initial studies have shown that calcimimetics can acutely lower parathyroid hormone leve
42                                              Calcimimetics can effectively reduce PTH secretion in al
43 bjective was to determine the effects of the calcimimetic cinacalcet (versus placebo) on reducing ser
44  recently confirmed the efficacy of the oral calcimimetic cinacalcet for achieving long-term reductio
45                                   The use of calcimimetic cinacalcet has been established to activate
46                                          The calcimimetic cinacalcet HCl acts on the calcium-sensing
47 l transduction, an effect rectified with the calcimimetic cinacalcet.
48 e IV calcimimetic etelcalcetide and the oral calcimimetic cinacalcet.
49 ine, Hepes buffer (pH 7.4), and CaR-specific calcimimetic, cinacalcet, stimulated gastrin and acid se
50              The novel mode of action of the calcimimetic, combined with the glucose-dependence of th
51             In this study we showed that the calcimimetic compound NPS R-467, a selective calcium-sen
52 g concentrations of calcium, neomycin, and a calcimimetic compound suppress PTHrP secretion by mammar
53                                              Calcimimetic compounds could conceivably provide a speci
54                             The discovery of calcimimetic compounds with potent and selective activit
55 he depolarization of the cell induced by the calcimimetic could be due to a direct action on the chan
56           An intravenously (IV) administered calcimimetic could improve adherence and reduce adverse
57  proteins in the presence and absence of the calcimimetic drug cinacalcet.
58 es bound to Ca(2+) and various calcilytic or calcimimetic drug molecules.
59                                          The calcimimetic drug R-568 reduces serum parathyroid hormon
60             We investigated the ability of a calcimimetic drug that inhibits parathyroid hormone secr
61 his asymmetry is stabilized by 7TM-targeting calcimimetic drugs adopting distinctly different poses i
62 m homeostasis in humans and is the target of calcimimetic drugs for the treatment of parathyroid diso
63 e the relative efficacy and safety of the IV calcimimetic etelcalcetide and the oral calcimimetic cin
64    To evaluate the effect of the intravenous calcimimetic etelcalcetide on serum parathyroid hormone
65 dentified 17 patients that were treated with calcimimetics for pHPT.
66 osphonates and a new class of drugs known as calcimimetics have been used effectively in some patient
67 y has been shown to improve BMD in pHPT, but calcimimetics have recently been advocated as a medical
68 This study aims to determine the efficacy of calcimimetics in improving bone mineral density (BMD) in
69 iol decreased osteoblastic activity, whereas calcimimetic increased bone cell activity.
70 milk protein concentration were mitigated by calcimimetic infusions.
71  given concentration of PTH, the addition of calcimimetics is associated with an increased bone cell
72                  An allosteric CaR agonist ("calcimimetic") is currently being tested for the treatme
73 um, strontium, aluminum, gadolinium, and the calcimimetic NPS 568 resulted in a dose-dependent stimul
74 luorescence imaging with fura-2, whether the calcimimetic NPS R-568 could activate Ca(2+)(i) oscillat
75                                          The calcimimetic NPS R-568 increases the potency of Ca2+ in
76 Conversely, stimulating endogenous CaSR with calcimimetic NPS-R568 accelerated wound re-epithelializa
77 lation of the calcium-sensing receptor using calcimimetic or calcilytic agents may allow the anabolic
78 s at up-regulating the parathyroid CaSR with calcimimetics or introducing earlier anti-resorptive tre
79 ultured cells, CaSR activation with high Ca, calcimimetics, or alkali increase shed Klotho levels via
80 oquinolones, antifungals, and, surprisingly, calcimimetics, phenothiazine antipsychotics, and polyaro
81                                              Calcimimetics promote CFTR opening by activating adenyla
82 treatment: (group 1) no treatment; (group 2) calcimimetic R-568 formulated in the diet; (group 3) R-5
83 cific CaR positive allosteric modulator, the calcimimetic R-568, mimics the suppressive effects of hi
84 stimulation of the CaSR, by Ca(2+) or by the calcimimetic R-568, produced a striking and time-depende
85 ntagonist lixivaptan in combination with the calcimimetic R-568, reduced cyst progression in two anim
86 t of ring constrained analogues of the known calcimimetic R-568.
87 show that pharmacological CaSR activation by calcimimetics stimulates lung fluid secretion through CF
88                                              Calcimimetics such as NPS (R)-N-(3-phenylpropyl)-alpha-m
89                                              Calcimimetics target the calcium-sensing receptor and lo
90  receptor (Casr) by both hypercalcemia and a calcimimetic that decreases PTH secretion, demonstrating
91 such as NPS R-568 are allosteric modulators (calcimimetics) that activate CaR by increasing the appar
92 f calcium-free intestinal phosphate binders, calcimimetics to control parathyroid hormone secretion a
93 ity of Calindol, a novel chemically distinct calcimimetic, to activate a Ca(2+) receptor construct (T
94 s normalized in 35% of patients treated with calcimimetics versus 76% of surgical patients (P = 0.036
95 ly, vascular calcification can be reduced by calcimimetics, which function as allosteric activators o
96                 For hyperparathyroid states, calcimimetics, which increase activation of the CaR, hav
97 he treatment of hyperparathyroidism known as calcimimetics, which reduce parathyroid hormone (PTH) sy